212 related articles for article (PubMed ID: 37917829)
1. Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines.
Chan K; Sathyamurthi PS; Queisser MA; Mullin M; Shrives H; Coe DM; Burley GA
Bioconjug Chem; 2023 Nov; 34(11):2049-2054. PubMed ID: 37917829
[TBL] [Abstract][Full Text] [Related]
2. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
[TBL] [Abstract][Full Text] [Related]
3. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
4. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
5. Bivalent Ligands for Protein Degradation in Drug Discovery.
Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
[TBL] [Abstract][Full Text] [Related]
6. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.
Mares A; Miah AH; Smith IED; Rackham M; Thawani AR; Cryan J; Haile PA; Votta BJ; Beal AM; Capriotti C; Reilly MA; Fisher DT; Zinn N; Bantscheff M; MacDonald TT; Vossenkamper A; Dace P; Churcher I; Benowitz AB; Watt G; Denyer J; Scott-Stevens P; Harling JD
Commun Biol; 2020 Mar; 3(1):140. PubMed ID: 32198438
[TBL] [Abstract][Full Text] [Related]
7. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
Yao R; Luo T; Wang M
Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
[TBL] [Abstract][Full Text] [Related]
8. Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.
Wang Z; Tan M; Su W; Huang W; Zhang J; Jia F; Cao G; Liu X; Song H; Ran H; Nie G; Wang H
J Med Chem; 2023 May; 66(9):6263-6273. PubMed ID: 37092695
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
10. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
Liu Z; Liu S
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506-Binding Protein 51 (FKBP51).
Geiger TM; Walz M; Meyners C; Kuehn A; Dreizler JK; Sugiarto WO; Maciel EVS; Zheng M; Lermyte F; Hausch F
Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202309706. PubMed ID: 37942685
[TBL] [Abstract][Full Text] [Related]
12. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
Yang W; Saboo S; Zhou L; Askin S; Bak A
Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
[TBL] [Abstract][Full Text] [Related]
13. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
14. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
15. Discovery of the First Potent, Selective, and
Sun Y; Xue Y; Sun P; Mu S; Liu H; Sun Y; Wang L; Wang J; Wu T; Yin W; Qin Q; Sun Y; Liu N; Wang H; Yang H; Zhao D; Cheng M
J Med Chem; 2023 Jun; 66(12):8200-8221. PubMed ID: 37279162
[TBL] [Abstract][Full Text] [Related]
16. Proteomic approaches advancing targeted protein degradation.
Sathe G; Sapkota GP
Trends Pharmacol Sci; 2023 Nov; 44(11):786-801. PubMed ID: 37778939
[TBL] [Abstract][Full Text] [Related]
17. Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature.
Trapotsi MA; Mouchet E; Williams G; Monteverde T; Juhani K; Turkki R; Miljković F; Martinsson A; Mervin L; Pryde KR; Müllers E; Barrett I; Engkvist O; Bender A; Moreau K
ACS Chem Biol; 2022 Jul; 17(7):1733-1744. PubMed ID: 35793809
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
19. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.
Schröder M; Renatus M; Liang X; Meili F; Zoller T; Ferrand S; Gauter F; Li X; Sigoillot F; Gleim S; Stachyra TM; Thomas JR; Begue D; Khoshouei M; Lefeuvre P; Andraos-Rey R; Chung B; Ma R; Pinch B; Hofmann A; Schirle M; Schmiedeberg N; Imbach P; Gorses D; Calkins K; Bauer-Probst B; Maschlej M; Niederst M; Maher R; Henault M; Alford J; Ahrne E; Tordella L; Hollingworth G; Thomä NH; Vulpetti A; Radimerski T; Holzer P; Carbonneau S; Thoma CR
Nat Commun; 2024 Jan; 15(1):275. PubMed ID: 38177131
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation.
Chen JJ; Jin JM; Gu WJ; Zhao Z; Yuan H; Zhou YD; Nagle DG; Xi QL; Zhang XM; Sun QY; Wu Y; Zhang WD; Luan X
Cancer Sci; 2023 May; 114(5):1958-1971. PubMed ID: 36692137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]